美股市場個股詳情
NAMSW NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM)
- 8.900
- 0.0000.00%
收盤價 10/23 11:45 (美東)
0.000最高價0.000最低價
0.000最高價0.000最低價0股成交量0.000今開8.900昨收0.00成交額0.00%換手率--市盈率(靜)0總股本14.67052周最高--市淨率0流通值0.99052周最低--股息TTM0流通股14.670歷史最高--股息率TTM0.00%振幅0.464歷史最低--平均價1股每手
關於NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM)公司
NewAmsterdam Pharma Co NV 是一家處於後研發階段的生物製藥公司，其使命是改善代謝性疾病患者的護理，這些疾病目前批准的療法尚未充分或耐受性良好。其產品 obicetrapib 是下一代口服低劑量 CETP 抑制劑，爲了克服當前 LDL-C 降低治療的侷限性。
公司介紹
公司代碼NAMSW
公司名稱NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM)
上市日期2021/02/08
成立日期2022
CEODr. Michael Harvey Davidson, M.D.
所屬市場納斯達克
員工數量29
年結日12-31
公司地址Gooimeer 2-35
城市Naarden
省份北荷蘭省
國家荷蘭
郵編1411 DC
電話31-35-206-29-71
董事高管
- 姓名
- 職務
- 年薪
- Dr. Michael Harvey Davidson, M.D.
- Chief Executive Officer and Director
- 580.56萬
- Louise Kooij
- Chief Accounting Officer
- --
- Juliette Audet
- Chief Business Officer
- 4.56萬
- William B.J. Jones, Jr
- Chief Commercial Officer
- --
- Ian Somaiya
- Chief Financial Officer
- 355.31萬
- Dr. Johannes Jacob Pieter Kastelein, M.D.
- Chief Scientific Officer and Director
- 297.86萬
- Douglas F. Kling
- Chief Operating Officer
- --
- William H. Lewis, J.D.,M.B.A.
- Chairman of the Board
- --
- Willian H Lewis
- Lead Independent Chairman of the Board
- --
- Dr. Nicholas S. Downing, M.D.
- Independent Director
- 4.73萬
- Wouter Joustra
- Independent Director
- --
- Louis G. Lange, M.D.
- Independent Director
- 33.91萬
- John W. Smither
- Independent Director
- 13.88萬
- Dr. James N. Topper, M.D.,PhD
- Independent Director
- 4.00萬
- Mark C. McKenna
- Independent Director
- --
- Janneke van der Kamp
- Independent Director
- 13.47萬